Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of LY900043 versus tirzepatide in adults with obesity or overweight and type 2 diabetes
jRCT2021260057Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3 trial of eloralintide and tirzepatide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in body weight. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
eloralintidetirzepatide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2021260057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260057.